Answers are grounded in this paper and cite their sources.
Different regulatory measures address EG/DEG contamination risk in pharmaceuticals, highlighting significant variations in jurisdictions.
Ethylene glycol (EG) and diethylene glycol (DEG) contamination of pharmaceutical excipients has repeatedly resulted in severe poisoning events, particularly in oral paediatric medicines, with fatalities continuing to be reported outside highly regulated regions. These incidents have largely been attributed to economically motivated adulteration of widely used excipients such as glycerol and propylene glycol. In response, regulatory authorities and pharmacopeial bodies have implemented measures to mitigate this risk; however, the scope, stringency, and regulatory philosophy of these measures vary significantly across jurisdictions.
No takes yet. Share an insight, caveat, or question.
Miquel Mir (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: